ID   HS3SA_HUMAN             Reviewed;         406 AA.
AC   Q9Y663; A8K7N2;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1999, sequence version 1.
DT   10-MAY-2017, entry version 134.
DE   RecName: Full=Heparan sulfate glucosamine 3-O-sulfotransferase 3A1;
DE            EC=2.8.2.30;
DE   AltName: Full=Heparan sulfate D-glucosaminyl 3-O-sulfotransferase 3A1;
DE            Short=3-OST-3A;
DE            Short=Heparan sulfate 3-O-sulfotransferase 3A1;
DE            Short=h3-OST-3A;
GN   Name=HS3ST3A1; Synonyms=3OST3A1, HS3ST3A; ORFNames=UNQ2551/PRO6180;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND TISSUE SPECIFICITY.
RC   TISSUE=Liver;
RX   PubMed=9988767; DOI=10.1074/jbc.274.8.5170;
RA   Shworak N.W., Liu J., Petros L.M., Zhang L., Kobayashi M.,
RA   Copeland N.G., Jenkins N.A., Rosenberg R.D.;
RT   "Multiple isoforms of heparan sulfate D-glucosaminyl 3-O-
RT   sulfotransferase. Isolation, characterization, and expression of human
RT   cDNAs and identification of distinct genomic loci.";
RL   J. Biol. Chem. 274:5170-5184(1999).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=12975309; DOI=10.1101/gr.1293003;
RA   Clark H.F., Gurney A.L., Abaya E., Baker K., Baldwin D.T., Brush J.,
RA   Chen J., Chow B., Chui C., Crowley C., Currell B., Deuel B., Dowd P.,
RA   Eaton D., Foster J.S., Grimaldi C., Gu Q., Hass P.E., Heldens S.,
RA   Huang A., Kim H.S., Klimowski L., Jin Y., Johnson S., Lee J.,
RA   Lewis L., Liao D., Mark M.R., Robbie E., Sanchez C., Schoenfeld J.,
RA   Seshagiri S., Simmons L., Singh J., Smith V., Stinson J., Vagts A.,
RA   Vandlen R.L., Watanabe C., Wieand D., Woods K., Xie M.-H.,
RA   Yansura D.G., Yi S., Yu G., Yuan J., Zhang M., Zhang Z., Goddard A.D.,
RA   Wood W.I., Godowski P.J., Gray A.M.;
RT   "The secreted protein discovery initiative (SPDI), a large-scale
RT   effort to identify novel human secreted and transmembrane proteins: a
RT   bioinformatics assessment.";
RL   Genome Res. 13:2265-2270(2003).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Spleen;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (SEP-2005) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Brain;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION IN HSV-1 ENTRY, AND MUTAGENESIS OF LYS-162.
RX   PubMed=10520990; DOI=10.1016/S0092-8674(00)80058-6;
RA   Shukla D., Liu J., Blaiklock P., Shworak N.W., Bai X., Esko J.D.,
RA   Cohen G.H., Eisenberg R.J., Rosenberg R.D., Spear P.G.;
RT   "A novel role for 3-O-sulfated heparan sulfate in herpes simplex virus
RT   1 entry.";
RL   Cell 99:13-22(1999).
RN   [7]
RP   CHARACTERIZATION.
RX   PubMed=9988768; DOI=10.1074/jbc.274.8.5185;
RA   Liu J., Shworak N.W., Sinay P., Schwartz J.J., Zhang L.,
RA   Fritze L.M.S., Rosenberg R.D.;
RT   "Expression of heparan sulfate D-glucosaminyl 3-O-sulfotransferase
RT   isoforms reveals novel substrate specificities.";
RL   J. Biol. Chem. 274:5185-5192(1999).
RN   [8]
RP   CHARACTERIZATION.
RX   PubMed=10608887; DOI=10.1074/jbc.274.53.38155;
RA   Liu J., Shriver Z., Blaiklock P., Yoshida K., Sasisekharan R.,
RA   Rosenberg R.D.;
RT   "Heparan sulfate D-glucosaminyl 3-O-sulfotransferase-3A sulfates N-
RT   unsubstituted glucosamine residues.";
RL   J. Biol. Chem. 274:38155-38162(1999).
RN   [9]
RP   X-RAY CRYSTALLOGRAPHY (1.85 ANGSTROMS) OF 139-406 IN A TERNARY COMPLEX
RP   WITH PAPS AND A TETRASACCHARIDE, DISULFIDE BOND, BINDING SITES, AND
RP   MUTAGENESIS OF LYS-161; LYS-162; ARG-166; GLU-170; ARG-173; GLY-182;
RP   GLU-184; HIS-186; ASP-189; ARG-190; LYS-194; LYS-215; SER-218;
RP   GLU-224; GLN-255; LYS-259; ILE-288; LYS-293; HIS-362; GLY-365;
RP   LYS-366; LYS-368 AND ARG-370.
RX   PubMed=15304505; DOI=10.1074/jbc.M405013200;
RA   Moon A.F., Edavettal S.C., Krahn J.M., Munoz E.M., Negishi M.,
RA   Linhardt R.J., Liu J., Pedersen L.C.;
RT   "Structural analysis of the sulfotransferase (3-o-sulfotransferase
RT   isoform 3) involved in the biosynthesis of an entry receptor for
RT   herpes simplex virus 1.";
RL   J. Biol. Chem. 279:45185-45193(2004).
CC   -!- FUNCTION: Sulfotransferase that utilizes 3'-phospho-5'-adenylyl
CC       sulfate (PAPS) to catalyze the transfer of a sulfo group to an N-
CC       unsubstituted glucosamine linked to a 2-O-sulfo iduronic acid unit
CC       on heparan sulfate. Catalyzes the O-sulfation of glucosamine in
CC       IdoUA2S-GlcNS and also in IdoUA2S-GlcNH2. The substrate-specific
CC       O-sulfation generates an enzyme-modified heparan sulfate which
CC       acts as a binding receptor to Herpes simplex virus-1 (HSV-1) and
CC       permits its entry. Unlike 3-OST-1, does not convert non-
CC       anticoagulant heparan sulfate to anticoagulant heparan sulfate.
CC       {ECO:0000269|PubMed:10520990}.
CC   -!- CATALYTIC ACTIVITY: 3'-phosphoadenylyl sulfate + [heparan
CC       sulfate]-glucosamine = adenosine 3',5'-bisphosphate + [heparan
CC       sulfate]-glucosamine 3-sulfate.
CC   -!- SUBCELLULAR LOCATION: Golgi apparatus membrane {ECO:0000305};
CC       Single-pass type II membrane protein {ECO:0000305}.
CC   -!- TISSUE SPECIFICITY: Ubiquitous. Most abundant in heart and
CC       placenta, followed by liver and kidney.
CC       {ECO:0000269|PubMed:9988767}.
CC   -!- SIMILARITY: Belongs to the sulfotransferase 1 family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; AF105376; AAD30208.1; -; mRNA.
DR   EMBL; AY358838; AAQ89197.1; -; mRNA.
DR   EMBL; AK292047; BAF84736.1; -; mRNA.
DR   EMBL; CH471108; EAW89959.1; -; Genomic_DNA.
DR   EMBL; BC044647; AAH44647.1; -; mRNA.
DR   CCDS; CCDS11165.1; -.
DR   RefSeq; NP_006033.1; NM_006042.2.
DR   UniGene; Hs.462270; -.
DR   UniGene; Hs.562745; -.
DR   PDB; 1T8T; X-ray; 1.85 A; A/B=139-406.
DR   PDB; 1T8U; X-ray; 1.95 A; A/B=139-406.
DR   PDBsum; 1T8T; -.
DR   PDBsum; 1T8U; -.
DR   ProteinModelPortal; Q9Y663; -.
DR   SMR; Q9Y663; -.
DR   BioGrid; 115280; 1.
DR   STRING; 9606.ENSP00000284110; -.
DR   DrugBank; DB01812; Adenosine-3'-5'-Diphosphate.
DR   DrugBank; DB04272; Citric Acid.
DR   DrugBank; DB02264; O2-Sulfo-Glucuronic Acid.
DR   iPTMnet; Q9Y663; -.
DR   PhosphoSitePlus; Q9Y663; -.
DR   BioMuta; HS3ST3A1; -.
DR   DMDM; 61214551; -.
DR   PaxDb; Q9Y663; -.
DR   PeptideAtlas; Q9Y663; -.
DR   PRIDE; Q9Y663; -.
DR   Ensembl; ENST00000284110; ENSP00000284110; ENSG00000153976.
DR   GeneID; 9955; -.
DR   KEGG; hsa:9955; -.
DR   UCSC; uc002gob.1; human.
DR   CTD; 9955; -.
DR   DisGeNET; 9955; -.
DR   GeneCards; HS3ST3A1; -.
DR   HGNC; HGNC:5196; HS3ST3A1.
DR   HPA; HPA062518; -.
DR   HPA; HPA071530; -.
DR   MIM; 604057; gene.
DR   neXtProt; NX_Q9Y663; -.
DR   OpenTargets; ENSG00000153976; -.
DR   PharmGKB; PA29469; -.
DR   eggNOG; KOG3704; Eukaryota.
DR   eggNOG; ENOG410XS59; LUCA.
DR   GeneTree; ENSGT00760000119023; -.
DR   HOGENOM; HOG000036663; -.
DR   HOVERGEN; HBG053377; -.
DR   InParanoid; Q9Y663; -.
DR   KO; K07809; -.
DR   OMA; VCVTLVY; -.
DR   OrthoDB; EOG091G0CS5; -.
DR   PhylomeDB; Q9Y663; -.
DR   TreeFam; TF350755; -.
DR   BioCyc; MetaCyc:HS07937-MONOMER; -.
DR   Reactome; R-HSA-2022928; HS-GAG biosynthesis.
DR   ChiTaRS; HS3ST3A1; human.
DR   EvolutionaryTrace; Q9Y663; -.
DR   GeneWiki; HS3ST3A1; -.
DR   GenomeRNAi; 9955; -.
DR   PRO; PR:Q9Y663; -.
DR   Proteomes; UP000005640; Chromosome 17.
DR   Bgee; ENSG00000153976; -.
DR   CleanEx; HS_HS3ST3A1; -.
DR   ExpressionAtlas; Q9Y663; baseline and differential.
DR   Genevisible; Q9Y663; HS.
DR   GO; GO:0000139; C:Golgi membrane; TAS:Reactome.
DR   GO; GO:0016021; C:integral component of membrane; TAS:ProtInc.
DR   GO; GO:0008467; F:[heparan sulfate]-glucosamine 3-sulfotransferase 1 activity; TAS:Reactome.
DR   GO; GO:0033872; F:[heparan sulfate]-glucosamine 3-sulfotransferase 3 activity; IEA:UniProtKB-EC.
DR   GO; GO:0008146; F:sulfotransferase activity; TAS:ProtInc.
DR   GO; GO:0006024; P:glycosaminoglycan biosynthetic process; TAS:Reactome.
DR   InterPro; IPR027417; P-loop_NTPase.
DR   InterPro; IPR000863; Sulfotransferase_dom.
DR   Pfam; PF00685; Sulfotransfer_1; 1.
DR   SUPFAM; SSF52540; SSF52540; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Complete proteome; Disulfide bond; Glycoprotein;
KW   Golgi apparatus; Membrane; Reference proteome; Signal-anchor;
KW   Transferase; Transmembrane; Transmembrane helix.
FT   CHAIN         1    406       Heparan sulfate glucosamine 3-O-
FT                                sulfotransferase 3A1.
FT                                /FTId=PRO_0000085217.
FT   TOPO_DOM      1     24       Cytoplasmic. {ECO:0000255}.
FT   TRANSMEM     25     43       Helical; Signal-anchor for type II
FT                                membrane protein. {ECO:0000255}.
FT   TOPO_DOM     44    406       Lumenal. {ECO:0000255}.
FT   NP_BIND     162    166       PAPS.
FT   NP_BIND     368    372       PAPS.
FT   REGION      184    190       Substrate binding.
FT   REGION      215    218       Substrate binding.
FT   REGION      255    259       Substrate binding.
FT   REGION      283    284       Substrate binding.
FT   REGION      367    370       Substrate binding.
FT   BINDING     166    166       Substrate.
FT   BINDING     243    243       PAPS.
FT   BINDING     251    251       PAPS.
FT   CARBOHYD    273    273       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   CARBOHYD    344    344       N-linked (GlcNAc...) asparagine.
FT                                {ECO:0000255}.
FT   DISULFID    351    363       {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     161    161       K->A: 99.6% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     162    162       K->A: 99.6% loss of enzymatic activity;
FT                                no HSV1 entry activity.
FT                                {ECO:0000269|PubMed:10520990,
FT                                ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     166    166       R->E: 99.8% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     170    170       E->Q: 17% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     173    173       R->S: 44.1% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     182    182       G->A: No effect on enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     184    184       E->Q: 99.9% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     186    186       H->F: Abolishes enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     189    189       D->N: 99.1% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     190    190       R->E: 32% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     194    194       K->A: 99.5% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     215    215       K->A: 99.9% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     218    218       S->A: 23.3% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     224    224       E->Q: 47.6% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     255    255       Q->A: 99.6% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     259    259       K->A: 48.3% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     288    288       I->A: 65% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     293    293       K->A: 33.6% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     362    362       H->A: No effect on enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     365    365       G->A: 43% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     366    366       K->A: 99.8% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     368    368       K->A: 99.9% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   MUTAGEN     370    370       R->E: 99.2% loss of enzymatic activity.
FT                                {ECO:0000269|PubMed:15304505}.
FT   HELIX       139    147       {ECO:0000244|PDB:1T8T}.
FT   STRAND      154    159       {ECO:0000244|PDB:1T8T}.
FT   HELIX       165    172       {ECO:0000244|PDB:1T8T}.
FT   STRAND      178    180       {ECO:0000244|PDB:1T8T}.
FT   TURN        187    190       {ECO:0000244|PDB:1T8T}.
FT   HELIX       192    194       {ECO:0000244|PDB:1T8T}.
FT   HELIX       195    202       {ECO:0000244|PDB:1T8T}.
FT   STRAND      211    215       {ECO:0000244|PDB:1T8T}.
FT   HELIX       217    221       {ECO:0000244|PDB:1T8T}.
FT   HELIX       225    232       {ECO:0000244|PDB:1T8T}.
FT   STRAND      237    242       {ECO:0000244|PDB:1T8T}.
FT   HELIX       245    259       {ECO:0000244|PDB:1T8T}.
FT   HELIX       266    270       {ECO:0000244|PDB:1T8T}.
FT   TURN        274    276       {ECO:0000244|PDB:1T8T}.
FT   HELIX       284    287       {ECO:0000244|PDB:1T8T}.
FT   HELIX       291    298       {ECO:0000244|PDB:1T8T}.
FT   TURN        299    301       {ECO:0000244|PDB:1T8T}.
FT   HELIX       304    306       {ECO:0000244|PDB:1T8T}.
FT   STRAND      307    311       {ECO:0000244|PDB:1T8T}.
FT   HELIX       312    317       {ECO:0000244|PDB:1T8T}.
FT   HELIX       319    330       {ECO:0000244|PDB:1T8T}.
FT   HELIX       338    340       {ECO:0000244|PDB:1T8T}.
FT   STRAND      341    344       {ECO:0000244|PDB:1T8T}.
FT   TURN        345    348       {ECO:0000244|PDB:1T8T}.
FT   STRAND      349    354       {ECO:0000244|PDB:1T8T}.
FT   HELIX       377    398       {ECO:0000244|PDB:1T8T}.
SQ   SEQUENCE   406 AA;  44900 MW;  57B6A0ABC897577A CRC64;
     MAPPGPASAL STSAEPLSRS IFRKFLLMLC SLLTSLYVFY CLAERCQTLS GPVVGLSGGG
     EEAGAPGGGV LAGGPRELAV WPAAAQRKRL LQLPQWRRRR PPAPRDDGEE AAWEEESPGL
     SGGPGGSGAG STVAEAPPGT LALLLDEGSK QLPQAIIIGV KKGGTRALLE FLRVHPDVRA
     VGAEPHFFDR SYDKGLAWYR DLMPRTLDGQ ITMEKTPSYF VTREAPARIS AMSKDTKLIV
     VVRDPVTRAI SDYTQTLSKR PDIPTFESLT FKNRTAGLID TSWSAIQIGI YAKHLEHWLR
     HFPIRQMLFV SGERLISDPA GELGRVQDFL GLKRIITDKH FYFNKTKGFP CLKKAEGSSR
     PHCLGKTKGR THPEIDREVV RRLREFYRPF NLKFYQMTGH DFGWDG
//
